Trial Protocol ID USOR 23189_DB-1303-O-3002_DYNASTY-Breast02

Trial Description

A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Courtney Ackerman, M.D.

Disease Types

Sponsors

  • Duality Biologics
  • IQVIA

ClinicalTrials.gov NCT ID

  • NCT06018337